Compare Stocks: CERO, RDHL, SILO, and JUNS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERO CERo Therapeutics	$0.01	$0.01	$0.01 ▼ $5.66	$860K	0.19	659,028 shs	422,382 shs
JUNS Jupiter Neurosciences	$2.95 -0.7%	$5.77	$2.86 ▼ $137.96	$2.69M	1.81	371,213 shs	6,305 shs
RDHL Redhill Biopharma	$0.54 -0.4%	$0.65	$0.52 ▼ $2.79	$3.29M	4.96	855,440 shs	27,957 shs
SILO Silo Pharma	$1.78 +0.3%	$3.16	$1.63 ▼ $13.20	$2.82M	0.66	186,122 shs	6,887 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERO CERo Therapeutics	0.00%	+20.00%	+20.00%	+20.00%	-99.78%
JUNS Jupiter Neurosciences	-0.34%	+1.37%	-47.53%	-83.26%	-97.00%
RDHL Redhill Biopharma	+0.39%	-1.25%	-10.26%	-36.86%	-66.48%
SILO Silo Pharma	+2.91%	+0.57%	-31.40%	-69.27%	-85.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERO CERo Therapeutics	$0.01	$0.01	$0.01 ▼ $5.66	$860K	0.19	659,028 shs	422,382 shs
JUNS Jupiter Neurosciences	$2.95 -0.7%	$5.77	$2.86 ▼ $137.96	$2.69M	1.81	371,213 shs	6,305 shs
RDHL Redhill Biopharma	$0.54 -0.4%	$0.65	$0.52 ▼ $2.79	$3.29M	4.96	855,440 shs	27,957 shs
SILO Silo Pharma	$1.78 +0.3%	$3.16	$1.63 ▼ $13.20	$2.82M	0.66	186,122 shs	6,887 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERO CERo Therapeutics	0.00%	+20.00%	+20.00%	+20.00%	-99.78%
JUNS Jupiter Neurosciences	-0.34%	+1.37%	-47.53%	-83.26%	-97.00%
RDHL Redhill Biopharma	+0.39%	-1.25%	-10.26%	-36.86%	-66.48%
SILO Silo Pharma	+2.91%	+0.57%	-31.40%	-69.27%	-85.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERO CERo Therapeutics	1.67	Reduce	$30.00	249,900.00% Upside
JUNS Jupiter Neurosciences	1.00	Sell	N/A	N/A
RDHL Redhill Biopharma	1.00	Sell	N/A	N/A
SILO Silo Pharma	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest CERO, RDHL, SILO, and JUNS Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/21/2026	JUNS Jupiter Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/21/2026	SILO Silo Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	RDHL Redhill Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/1/2026	SILO Silo Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	JUNS Jupiter Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERO CERo Therapeutics	N/A	N/A	N/A	N/A	($41.98) per share	N/A
JUNS Jupiter Neurosciences	$64.69K	41.62	N/A	N/A	($4.00) per share	-0.74
RDHL Redhill Biopharma	$290K	11.34	N/A	N/A	$0.83 per share	0.65
SILO Silo Pharma	$70K	40.32	N/A	N/A	$7.10 per share	0.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERO CERo Therapeutics	-$8.30M	-$9.84	N/A	N/A	N/A	N/A	N/A	-209.40%	12/2/2026 (Estimated)
JUNS Jupiter Neurosciences	-$8.65M	-$19.12	N/A	N/A	N/A	N/A	-1,314.62%	-246.66%	12/2/2026 (Estimated)
RDHL Redhill Biopharma	-$430K	$900.00	0.00	N/A	N/A	N/A	N/A	N/A	N/A
SILO Silo Pharma	-$4.23M	-$4.36	N/A	N/A	N/A	-6,726.39%	-81.75%	-66.35%	12/2/2026 (Estimated)

Latest CERO, RDHL, SILO, and JUNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	JUNS Jupiter Neurosciences	-$3.75	-$5.06	-$1.31	-$4.08	$0.40 million	$0.02 million
8/13/2026	Q2 2026	SILO Silo Pharma	-$0.32	-$0.76	-$0.44	-$0.76	$0.02 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERO CERo Therapeutics	N/A	N/A	N/A	N/A	N/A
JUNS Jupiter Neurosciences	N/A	N/A	N/A	N/A	N/A
RDHL Redhill Biopharma	N/A	N/A	N/A	N/A	N/A
SILO Silo Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERO CERo Therapeutics	N/A	0.56	0.56
JUNS Jupiter Neurosciences	N/A	0.66	0.62
RDHL Redhill Biopharma	N/A	0.34	0.34
SILO Silo Pharma	N/A	5.36	5.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERO CERo Therapeutics	29.64%
JUNS Jupiter Neurosciences	N/A
RDHL Redhill Biopharma	7.20%
SILO Silo Pharma	5.58%

Insider Ownership

Company	Insider Ownership
CERO CERo Therapeutics	0.36%
JUNS Jupiter Neurosciences	38.60%
RDHL Redhill Biopharma	6.81%
SILO Silo Pharma	3.63%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERO CERo Therapeutics	8	71.63 million	1.05 million	N/A
JUNS Jupiter Neurosciences	5	913,000	561,000	Not Optionable
RDHL Redhill Biopharma	210	6.08 million	5.67 million	No Data
SILO Silo Pharma	3	1.59 million	1.53 million	Not Optionable

CERO, RDHL, SILO, and JUNS Headlines

Recent News About These Companies

Silo Pharma Gets U.S. Patent Allowance For SPC-15 PTSD Treatment

September 18, 2026 | rttnews.com

Silo Pharma Receives U.S. Patent Allowance For SPC-15 Ptsd Treatment

September 18, 2026 | marketscreener.comM

Silo Pharma Receives USPTO Notice of Allowance for SPC-15 Patent Covering Stress-Induced Behavioral Response Prevention

September 18, 2026 | quiverquant.comQ

Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio

September 18, 2026 | globenewswire.com

Silo Pharma To Highlight SPC-15 Nose-To-Brain Technology At 2026 Nasal Innovation Forum

September 9, 2026 | rttnews.com

Silo Pharma to Participate in IPAC-RS 2026 Nasal Innovation Forum as It Advances SPC-15 Development

September 9, 2026 | quiverquant.comQ

Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum

September 9, 2026 | globenewswire.com

Silo Pharma’s lead asset SPC-15, an intranasal 5-HT4 receptor agonist targeting post-traumatic stress disorder receives Canadian patent

August 20, 2026 | pharmabiz.comP

Silo Pharma Gets Canadian Patent Allowance for Stress Disorder Treatment

August 20, 2026 | finance.yahoo.com

Silo Pharma Acquires Digital Assets via Stock Issuance

August 19, 2026 | tipranks.com

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

August 18, 2026 | globenewswire.com

Silo Pharma Granted European Patent Covering Novel PTSD Therapy

August 10, 2026 | markets.businessinsider.com

Silo Pharma Announces European Patent Grant for SPC-15 PTSD Prevention Therapy

August 10, 2026 | quiverquant.comQ

Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform

August 6, 2026 | globenewswire.com

Silo Pharma Advances QwikAgents Commercial Launch and SPC-15 Development

July 21, 2026 | quiverquant.comQ

Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

July 21, 2026 | globenewswire.com

Is Silo Pharma, Inc. (SILO) Stock an AI Opportunity After NVIDIA Partnership Boosts QwikAgents Platform?

July 15, 2026 | insidermonkey.com

Silo Pharma’s QwikAgents joins AMD AI developer program to advance AI agent platform

July 14, 2026 | msn.com

Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership

July 14, 2026 | benzinga.com

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

July 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO, RDHL, SILO, and JUNS Company Descriptions

CERo Therapeutics NASDAQ:CERO

$0.01 0.00 (0.00%)

As of 09/23/2026 03:39 PM Eastern

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Jupiter Neurosciences NASDAQ:JUNS

$2.95 -0.02 (-0.71%)

As of 10:45 AM Eastern

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

Redhill Biopharma NASDAQ:RDHL

$0.54 0.00 (-0.39%)

As of 10:47 AM Eastern

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Silo Pharma NASDAQ:SILO

$1.78 +0.01 (+0.28%)

As of 10:48 AM Eastern

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CERO, RDHL, SILO, and JUNS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CERO, RDHL, SILO, and JUNS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CERO, RDHL, SILO, and JUNS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO, RDHL, SILO, and JUNS Company Descriptions

CERo Therapeutics NASDAQ:CERO

Jupiter Neurosciences NASDAQ:JUNS

Redhill Biopharma NASDAQ:RDHL

Silo Pharma NASDAQ:SILO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CERO, RDHL, SILO, and JUNS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CERO, RDHL, SILO, and JUNS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CERO, RDHL, SILO, and JUNS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO, RDHL, SILO, and JUNS Company Descriptions

CERo Therapeutics NASDAQ:CERO

Jupiter Neurosciences NASDAQ:JUNS

Redhill Biopharma NASDAQ:RDHL

Silo Pharma NASDAQ:SILO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools